These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 110880)

  • 1. Active disassembly of the first complement component, C-1, by C-1 inactivator.
    Ziccardi RJ; Cooper NR
    J Immunol; 1979 Aug; 123(2):788-92. PubMed ID: 110880
    [No Abstract]   [Full Text] [Related]  

  • 2. The first component of complement. I. Purification and properties of native C1.
    Medicus RG; Chapuis RM
    J Immunol; 1980 Jul; 125(1):390-5. PubMed ID: 7381205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The classical complement pathway: activation and regulation of the first complement component.
    Cooper NR
    Adv Immunol; 1985; 37():151-216. PubMed ID: 3890478
    [No Abstract]   [Full Text] [Related]  

  • 4. C1 dissociation. Spontaneous generation in human serum of a trimer complex containing C1 inactivator, activated C1r, and zymogen C1s.
    Laurell AB; Mårtensson U; Sjöholm AG
    J Immunol; 1987 Dec; 139(12):4145-51. PubMed ID: 2826582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes.
    Sim RB; Arlaud GJ; Colomb MG
    Biochem J; 1979 Jun; 179(3):449-57. PubMed ID: 475762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and partial characterization of a C1q inhibitor from the membranes of human peripheral blood lymphocytes.
    Ghebrehiwet B; Hamburger M
    J Immunol; 1982 Jul; 129(1):157-62. PubMed ID: 6979565
    [No Abstract]   [Full Text] [Related]  

  • 7. The relationship between the binding ability and the rate of activation of the complement component C1.
    Folkerd EJ; Gardner B; Hughes-Jones NC
    Immunology; 1980 Sep; 41(1):179-85. PubMed ID: 7429549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The first component of complement from the bullfrog, Rana catesbeiana: functional properties of C1- and isolation of subcomponent C1q.
    Alexander RJ; Steiner LA
    J Immunol; 1980 Mar; 124(3):1418-25. PubMed ID: 6965693
    [No Abstract]   [Full Text] [Related]  

  • 9. [Functions and structure of complement inactivators in plasma. 1). C1 inhibitor].
    Yonemasu K
    Nihon Rinsho; 1988 Sep; 46(9):1899-903. PubMed ID: 3266510
    [No Abstract]   [Full Text] [Related]  

  • 10. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.
    Bokisch VA; Müller-Eberhard HJ
    J Clin Invest; 1970 Dec; 49(12):2427-36. PubMed ID: 4098172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the antigenicity of C1r and C1s by C1 inactivator.
    Ziccardi RJ; Cooper NR
    J Immunol; 1978 Dec; 121(6):2148-52. PubMed ID: 722073
    [No Abstract]   [Full Text] [Related]  

  • 12. Different behaviour of native and purified C1 q, a subcomponent of the first component of complement (C1).
    Loos M; Hill HU
    Monogr Allergy; 1977; 12():46-51. PubMed ID: 335219
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
    Schifferli JA; Steiger G; Schapira M
    Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of activation of human T lymphocytes by the complement C1 esterase inhibitor.
    Eriksson H; Sjögren HO
    Immunology; 1995 Oct; 86(2):304-10. PubMed ID: 7490133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on human plasma C1 inactivator-enzyme interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema.
    Harpel PC; Hugli TE; Cooper NR
    J Clin Invest; 1975 Mar; 55(3):605-11. PubMed ID: 123252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-independent activation of C1. II. Evidence for two classes of nonimmune activators of the classical pathway of complement.
    Peitsch MC; Kovacsovics TJ; Tschopp J; Isliker H
    J Immunol; 1987 Mar; 138(6):1871-6. PubMed ID: 3029223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for direct binding of the first component of complement, C1, to outer membrane proteins from Salmonella minnesota.
    Stemmer F; Loos M
    Curr Top Microbiol Immunol; 1985; 121():73-84. PubMed ID: 3878768
    [No Abstract]   [Full Text] [Related]  

  • 19. Interaction of Neisseria gonorrhoeae with classical complement components, C1-inhibitor, and a monoclonal antibody directed against the Neisserial H.8 antigen.
    Schweinle JE; Hitchcock PJ; Tenner AJ; Hammer CH; Frank MM; Joiner KA
    J Clin Invest; 1989 Feb; 83(2):397-403. PubMed ID: 2492308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoantibody-facilitated proteolytic cleavage: a new pathogenic mechanism in autoimmunity.
    Jackson J
    Biochem Soc Trans; 1991 Feb; 19(1):176-80. PubMed ID: 2037141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.